ClinicalTrials.gg
Not yet recruitingNCT06258291RESTORE IUpdated Mar 14, 2025

First in Human Trial to Assess the Feasibility and Preliminary Safety of Adjunctive Treatment with the HemoSystem REBOOT in Critically Ill Patients with Sepsis-induced Immunosuppression

An interventional study of Hemosystem REBOOT in Septic Shock, sponsored by hemotune AG. Not yet recruiting at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by hemotune AG · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Shock, Septic with a site in Switzerland — 6 open to participants now, 6 under way, 1 of them phase 3. Shock, Septic · Switzerland.

Planned enrollment
13th of 13
16 · median 170
Started
2025
with 2 others
No phase
7 of 18
3 open now
Registered
16th of 18
by date
Lead sponsor
1 of 18
hemotune AG

Among the 18 studies in Shock, Septic with a site in Switzerland, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 with no phase, and was the 16th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

6 of the 18 studies in Shock, Septic with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Shock, Septic with a site in Switzerland, or all of them as a file.
02

Study summary

The aim of this randomized controlled trial is to restore immune function by selectively removing three mediators largely contributing to sepsis-induced immunosuppression from extracorporeal circulation.

Read the detailed description

The treatment safety and the kinetics of specific biomarkers will be assessed to evaluate the selection of the treatment regimen. In a first step, 16 patients will be randomized 1:1 into two arms:

Treatment arm 1: One treatment of 2 hours per day for a maximum of five days or until ICU discharge or death or withdrawal of consent, whichever occurs first.

Control arm: Five consecutive days following the first mHLA-DR measurement post study randomization, or until ICU discharge or death or withdrawal of consent, whichever occurs first

And the end of this treatment phase, it will be decided whether the dosage regimen of HemoSystem REBOOT needs to be adapted and another eight patients have to be enrolled with 2 treatments per day, and a maximum of five treatments.

03

Conditions studied

  • Septic Shock

Browse trials for

Keywords

  • immunosuppression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Written according to national requirements.
  3. Hospitalized in ICU or IMC at randomization.
  4. Expected length of intensive care unit stay (from randomization) >48 hours.
  5. Suspected or confirmed bacterial sepsis.
  6. Septic shock diagnosis at any time during ICU/IMC stay according to Sepsis - 3 criteria definition:

    1. an infection (suspected or confirmed);
    2. persisting hypotension requiring any dose of vasopressors (norepinephrine, vasopressin) to maintain a systemic mean blood pressure > 65 mmHg despite adequate fluid resuscitation (minimum of 30 ml/kg crystalloids);
    3. elevated lactate ≥ 2.0 mmol/L with suspected hypoperfusion.
  7. Persistent defined as mHLA-DR expression levels \< 5600 Ab/cell (Cyto-Chex tubes) in at least two consecutive measurements 20-72 hours apart.

Exclusion criteria

Exclusion criteria:

  1. Current ongoing chronic treatment using biologicals or active lymphocyte therapy (e.g. endoxan, rituximab) or use at a dose > 10 mg/day equivalent of prednisone. However, acute treatment using a maximum dose of hydrocortisone of 200 mg/day for sepsis is allowed.
  2. Patient with preexisting known severe immune deficiency (e.g. severe combined immunodeficiency, infection, AIDS).
  3. Active or planned extracorporeal membrane oxygenation treatment.
  4. Active or planned other extracorporeal blood purification treatments with systems like CytoSorb®, ToraymyxinTM, Gambro Adsorba, etc.
  5. Patients post solid-organ transplantation.
  6. Known active (i.e. patients under active anti-malignant treatment).
  7. Acute severe burn injury > 20% of the body surface area.
  8. to use the HemoSystem:

    1. Sensitivity / allergy to HemoSystem components
    2. Body weight \< 50 kg
    3. count \< 20,000/µL
    4. History of heparin-induced thrombocytopenia.
  9. Females who are known to be pregnant or known to be breastfeeding (b-HCG testing performed in female patients aged \< 55 years),
  10. Moribund patient with \< 48h
  11. Known history of bleeding disorders or severe coagulopathies (e.g., Hemophilia A, Hemophilia B, Idiopathic Thrombocytopenic Purpura, Von Willebrand Disease types I, II, and III)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Treatment arm

    The REBOOT Hemosystem will be tested in the treatment arm for a maximum of 5 treatments, the treatment will be applied in addition to standard of care alone.

    Device: Hemosystem REBOOT

  • No intervention
    Standard of care

    Best standard of care will be applied to these patients.

Interventions

  • DeviceHemosystem REBOOT

    The HemoSystem REBOOT will selectively remove three mediators largely contributing to sepsis-induced immunosuppression, from extracorporeal circulation based on magnetic beads.

    Also known as: extracorporeal blood purification

06

What researchers measure

Primary outcomes

  1. Biomarker for sepsis induced immunosuppression (monocytic HLA-DR = mHLA-DR)

    Change in mHLA-DR levels during treatment compared to the standard of care arm alone

    Time frame: pre-procedure immune marker levels compared to post-treatment levels at least 24 hours after last treatment (on average estimated day 6 after treatment start)

Secondary outcomes

  1. To determine all-cause mortality up to 90 days follow-up

    Difference in mortality between treatment arm and standard of care arm

    Time frame: through the end of the study (on average 90 days follow up)

  2. Need for organ support therapy (the number of days on organ support in the intensive care unit (index admission) defined by (1) invasive mechanical ventilation, (2) Intermittent or continuous renal replacement therapy, (3) any vasopressor support.

    Difference between treatment arm and standard of care arm

    Time frame: until the end of the initial ICU admission (on average day 10 after initial ICU admission)

  3. To assess the total number of organ support free days in intensive and intermediate care unit

    Difference in total number of organ support free days between treatment arm and standard of care arm

    Time frame: until the end of the initial ICU admission (on average day 10 after initial ICU admission)

  4. To assess the change of Sequential Organ Failure Assessment (SOFA) score (ranging from 0 =normal to 4=significantly impaired per category)

    Difference in SOFA score between treatment arm and standard of care arm

    Time frame: through the end of the study (on average 90 days follow up)

  5. To assess vasopressor doses during intensive and intermediate care unit stay

    To assess the difference in dosing between the treatment arm and standard of care arm

    Time frame: until the end of the initial ICU admission (on average day 10 after initial ICU admission)

  6. To assess the use of antimicrobial medication

    Difference in days on antimicrobials vs days off antimicrobials between treatment arm and standard of care arm

    Time frame: through the end of the study (on average 90 days follow up)

  7. To evaluate the change in the biomarker (for sepsis-induced immunosuppression) mHLA-DR concentration at various timepoints during ICU stay

    Difference in immune markers between treatment arm and standard of care arm will be compared

    Time frame: at admission to ICU, on the day of first, 2nd, 3rd, 4th, and 5th treatment, and daily up to 72 hours after last treatment.

  8. To assess the technical success of in vivo target removal

    Technical success rate in treatment arm

    Time frame: immediately after last treatment

  9. Number of SADEs in treatment arm

    SADE rate

    Time frame: through the end of the study (on average 90 days follow up)

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jul 2026, 10 months later.

Of 173 interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2024
First posted
Feb 14, 2024
StartEst.
Sep 1, 2025
Primary completionEst.
Jul 28, 2026
CompletionEst.
Dec 30, 2026
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06258291
Lead sponsor
hemotune AG
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Sep 1, 2025 (estimated)
Primary completion
Jul 28, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 14, 2025

Study contacts

Stephanie Sauter, PhD
Contact
stephanie.sauter@hemotune.ch
+41765182096
Joerg Schefold, Prof
principal investigator · University Hospital Berne, Inselspital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion